<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) July 1, 1998
------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- -------------------------------------- ---------- ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ------------------------------------------ ------------------------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
On July 1, 1998, Boston Life Sciences, Inc. announced that it had submitted an
amendment to the pending NDA for THERAFECTIN. The amendment is comprised of the
results of the Company's Phase III trial of THERAFECTIN as well as the
manufacturing data pertaining to the clinical supplies used in the study. The
results of the trial had previously been summarized in a January 20, 1998
Company Press Release. The Company has requested marketing approval based on the
results of the trial and the previous data contained in the THERAFECTIN NDA.
THERAFECTIN is a carbohydrate-based small molecule that has been developed as an
oral treatment of Rheumatoid Arthritis. The Company believes, based on its
favorable safety profile and convenient oral dosing, that THERAFECTIN, if
approved, could receive significant market acceptance.
On July 14, 1998, Boston Life Sciences, Inc. announced that in animal studies,
BLSI's anti-angiogenic product Troponin I appeared to inhibit blood vessel
formation in an animal eye model of retinal neovascularization. Prior animal
studies had also indicated that Troponin inhibited metastatic tumor growth. A
single intra-ocular injection of Troponin significantly inhibited retinal
angiogenesis in this model. The Company considers these results highly
encouraging, since it did not optimize either dosing or delivery of Troponin to
the retina in these experiments. Based on these results, the Company hopes to
move forward as rapidly as possible with the development of Troponin for the
potential treatment of Macular Degeneration and Diabetic Retinopathy, two
important angiogenic eye diseases affecting millions of individuals.
Discussions with potential corporate partners to co-develop these and
potentially other ophthalmic indications are ongoing, although no specific
agreements have yet been reached.
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated July 1, 1998.
99.2 Press Release, dated July 14, 1998
1
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: July 27, 1998 By: /s/ Joseph Hernon
-----------------------
Joseph Hernon
Chief Financial Officer
2
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page(s)
- ----------- -------
99.1 Press Release, dated July 1, 1998 4
99.2 Press Release, dated July 14, 1998 5
3
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
---------------------
BOSTON LIFE SCIENCES ANNOUNCES SUBMISSION OF NDA AMENDMENT FOR THERAFECTIN/R/
Boston, MA--July 1, 1998. Boston Life Sciences, Inc. (NASDAQ: BLSI) announced
that it had submitted an amendment to the pending NDA for THERAFECTIN. The
amendment is comprised of the results of the Company's Phase III trial of
THERAFECTIN as well as the manufacturing data pertaining to the clinical
supplies used in the study. The results of the trial had previously been
summarized in a January 20, 1998 Company Press Release. The Company has
requested marketing approval based on the results of the trial and the previous
data contained in the THERAFECTIN NDA.
THERAFECTIN is a carbohydrate-based small molecule that has been developed as an
oral treatment of Rheumatoid Arthritis. "We believe, based on its favorable
safety profile and convenient oral dosing, that THERAFECTIN, if approved, would
receive significant market acceptance", said Marc Lanser, MD, Chief Scientific
Officer at BLSI.
BLSI is developing novel treatments for cancer, autoimmune disease, and central
nervous system disorders. In addition to THERAFECTIN, products in clinical
trials or in preclinical development by BLSI include Troponin I, a naturally-
occurring anti-angiogenesis factor for the potential treatment of solid tumors;
AF1 for the potential treatment of stroke and spinal cord injury; Altropane, a
radioimaging agent for the diagnosis of Parkinson's Disease; and transcription
factors that may control the expression of molecules associated with autoimmune
disease and allergies.
This press release contains forward-looking statements regarding market
prospects for THERAFECTIN. Actual results may vary materially, and there can be
no assurance that regulatory approval will be obtained, or that if obtained,
that THERAFECTIN will receive significant market acceptance.
For additional information contact:
David Hillson
President and CEO
617-425-0200
4
<PAGE>
Exhibit 99.2
FOR IMMEDIATE RELEASE
---------------------
BOSTON LIFE SCIENCES' ANTI-ANGIOGENIC TROPONIN IS SHOWN IN ANIMAL
STUDIES TO INHIBIT RETINAL ANGIOGENESIS
Boston, MA --July, 14, 1998. Boston Life Sciences, Inc. (NASDAQ: BLSI)
announced that in animal studies, BLSI's anti-angiogenic product Troponin I
appeared to inhibit blood vessel formation in an animal eye model of retinal
neovascularization. Prior animal studies had also indicated that Troponin
inhibited metastatic tumor growth.
A single intra-ocular injection of Troponin significantly (p less than 0.0005)
inhibited retinal angiogenesis in this model. "In addition to our gratifying
results in the treatment of cancer, we are pleased to have received further
evidence of Troponin's potent anti-angiogenic activity in an additional model of
angiogenesis", stated Marc Lanser, MD, Chief Scientific Officer of BLSI. "We
consider these results highly encouraging, since we did not optimize either
dosing or delivery of Troponin to the retina in these experiments. Therefore in
addition to development for cancer applications, we hope to move forward as
rapidly as possible with the development of Troponin for the potential treatment
of Macular Degeneration and Diabetic Retinopathy, two important angiogenic eye
diseases affecting millions of individuals. Discussions with potential corporate
partners to co-develop these and potentially other ophthalmic indications are
ongoing, although no specific agreements have yet been reached," said Dr.
Lanser.
BLSI is developing novel treatments for cancer, autoimmune disease, and central
nervous system disorders. In addition to Troponin I, a naturally-occurring
anti-angiogenesis factor for the potential treatment of solid tumors and eye
diseases, products under FDA review, in clinical trials or in preclinical
development by BLSI include THERAFECTIN for the treatment of Rheumatoid
Arthritis; AF-1 for the potential treatment of stroke and spinal cord injury;
Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease; and
transcription factors that may control the expression of molecules associated
with autoimmune disease and allergies.
The foregoing contains certain forward-looking statements with regard to product
development timelines and corporate partnering discussions, which may not be
realized due to the uncertainties inherent in the research and development and
negotiating processes.
For further information please contact:
Marc E. Lanser, MD
Chief Scientific Officer
617-425-0200
5
